IP Library › Assignment 013957/0709
Patent Assignment
Reel/Frame 013957/0709

Security Agreement

Recorded: 2003-09-10 Received: 2003-09-10 Pages: 22
Assignor
ENANTA PHARMACEUTICALS, INC.
Executed: 2003-07-10
Assignee
SILICON VALLEY BANK DBA SILICON VALLEY EAST
3003 TASMAN DRIVE, SANTA CLARA, CA, 95054, UNITED STATES
Covered Properties (49)
6,11-4C-Bicyclic 9A-Azalide Derivatives
Application: 10/464,188 →
Bicyclic Macrolide Derivatives
Application: 10/455,219 →
6-O-Substituted Bicyclic Ketolides
Application: 10/454,865 →
6-O-Substituted Bicyclic Macrolides
Application: 10/455,001 →
Bicyclic Ketolide Derivatives
Application: 10/455,648 →
6,11-Bicyclic Erythromycin Derivatives
Application: 10/436,622 →
6-11 Bicyclic Ketolide Derivatives
Application: 10/429,485 →
6,11-3C-Bicyclic 9A-Azalide Derivatives
Application: 10/397,923 →
Cyclosporins for the Treatment of Immune Disorders
Application: 10/360,894 →
Mu opioid receptor ligands: methods of use and synthesis
Application: 60/443,428 →
Cyclosporins for the Treatment of Immune Disorders
Application: 10/349,890 →
Cyclosporins for the Treatment of Immune Disorders
Application: 10/349,877 →
Cyclosporin analogs for the treatment of lung diseases
Application: 10/345,855 →
Cyclosporins for the treatment of respiratory diseases
Application: 10/345,866 →
Cyclosporins for the treatment of immune disorders
Application: 10/309,934 →
Novel Anhydrolide Derivatives Having Antibacterial Activity
Application: 10/289,820 →
Methods and Compositions for Identifying Peptide Aptamers Capable of Altering a Cell Phenotype
Cyclosporin Analogs for the Treatment of Autoimmune Diseases
Cyclosporin Anlogs for Treatment of Lung Diseases
Methods for identifying peptide aptamers capable of altering a cell phenotype
Application: 10/263,577 →
Novel 11,12-Substituted Lactone Ketolide Derivatives Having Antibacterial Activity
Application: 10/223,144 →
4-Substituted Leucomycins
6,11-4-Carbon Bridged Ketolides
Application: 10/205,018 →
6, 11-4-Carbon Bridged Erythromycin Derivatives
Application: 10/205,357 →
11-C-Substituted Ketolides
Application: 10/179,590 →
11-C-Substituted Derivatives of Clarithromycin
Application: 10/178,991 →
6-11 bicyclic erythromycin derivatives
Application: 10/144,396 →
6-11 bicyclic ketolide derivatives
Application: 10/144,558 →
5-O-Mycaminosyltylonide Derivatives
Application: 10/125,840 →
23-O-Substituted 5-O-Mycaminosyltylonide Derivatives
Application: 10/126,076 →
Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
Application: 60/357,278 →
Bicyclic Leucomycins
9-Amino-14-Membered Macrolide Devived from Leucomycin
Novel 11-O-Substituted Ketolide Derivatives
Application: 10/011,642 →
11-O-Substituted Macrolides and Their Descladinose Derivatives
Application: 10/011,322 →
Novel Tylosin Derivatives Having Antibacterial Activity
Application: 10/002,918 →
4'-O-Substituted Tylosin Analogs
Application: 10/007,744 →
Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
Application: 60/333,262 →
Nitrogen Heterocycle Inhibitors of Aspartyl Protease
Application: 10/007,342 →
Alpha-Hydroxyarylbutanamine Inhibitors of Aspartyl Protease
Application: 10/007,235 →
Cyclosporin Analogs for the Treatment of Autoimmune Diseases
Application: 09/976,219 →
Cyclosporin analogs for the treatment of lung diseases
Application: 09/975,923 →
Synthesis of Compounds and Libraries of Compounds
Application: 09/949,280 →
4' -Substituted Leucomycins
Application: 09/917,107 →
Stimulating Transport of Glucose into Animal Tissue by the Administration of Pinitol
Application: 09/857,245 →
9-Amino-14-Membered Macrolides Derived from Leucomycins
Application: 09/824,318 →
Cyclosporins for the Treatment of Respiratory Diseases
Application: 09/800,856 →
Bicyclic Leucomycins
Application: 09/785,727 →
Cyclosporins for the Treatment of Respiratory Diseases